At Mylan, delivering better health for a better U.S. isn’t our job. It's our mission.


We believe everyone deserves the opportunity to live a healthy life, including you. That’s why, for more than 55 years, Mylan has been committed to providing access to high quality medicine and setting new standards in healthcare.

Better Health for a Better U.S.
See Mylan's impact in your  

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine.


Mylan was founded in the U.S. in 1961 by two Army buddies who wanted to make medicine accessible to people living in rural West Virginia. From those humble beginnings, the company grew tremendously in the years that followed.

Today, we market more than 7,500 products worldwide, including prescription generic and brand-name medicines as well as consumer health products. We also offer services and patient-support programs.

68 billion
doses of medicine provided by Mylan around the world
>6,000
people working in Quality globally
~3,000
Scientific and Regulatory Affairs experts globally
7,500
Products marketed worldwide
165
We serve patients in more than 165 countries and territories.
50 manufacturing sites worldwide
35,000+
global workforce

Committed to Access

We believe access to healthcare should be a right, not a privilege.


That makes our mission very personal. After all, everyone we’re trying to reach is somebody’s friend, neighbor or family member, including our own. In fact, our quality products probably are in your medicine cabinet now.


Learn how Mylan is your champion.

Substantial Savings

Mylan knows people are concerned about the price of prescription drugs. So are we. That’s why we continue to leverage our heritage as a generic drug manufacturer.

In 2016, generics filled 89% of all prescriptions dispensed in the U.S., saving our healthcare system billions of dollars.
$253 billion
in savings from generics
~$25 billion
in savings from Mylan generics
U.S. Portfolio

Medicines You Need

Mylan is a leader today in offering medications that address a range of health concerns around the world – from the common cold to serious diseases like cancer, autoimmune disorders, diabetes, respiratory conditions and Alzheimer’s.

25¢ per dose
was the average selling price in 2016 of Mylan’s medicines in the U.S., branded and generic.
1 out of every 13
prescriptions dispensed in the U.S., brand name or generic, is filled with a Mylan product.
635 products
are offered by Mylan in the U.S.

Mylan products filled more prescriptions in 2016 than AstraZeneca, GSK, Johnson & Johnson, Lilly, Merck, Pfizer and Sanofi COMBINED.

Mylan is a leader in the fight against many of our nation’s most prevalent diseases.

From Our Medicine Cabinet to Yours

Mylan does everything possible to make sure our life-changing medicines are always in stock where patients – and their doctors, nurses or caregivers – expect them to be. Peace of mind is great medicine, too.

~20B
doses of medicine produced by Mylan in the U.S. each year.
~80%
of the doses Mylan sells in the U.S. are made in America.
~$3B
invested by Mylan in capital expenditures globally, which includes a significant investment in manufacturing, over the last decade.

Mylan produces active pharmaceutical ingredients and finished medicines, giving us substantial control over their cost and quality.



Watch how Mylan tablets and capsules are made.

Healthcare You Deserve

Going Beyond Medicine

Because there’s more to delivering better health than offering quality medicine, Mylan thinks in terms of fighting disease. Doing so reveals opportunities to wrap our products in services focused on wellness, prevention and adherence, such as reminders to refill prescriptions

>1.5M
people diagnosed with cancer each year in the U.S.

Mylan is one of the largest suppliers of cancer medicines by volume in the U.S.

~1 in 10
women aged 20 and older have diabetes

Mylan is a leading producer of oral diabetes medicines.

16.5M
people receive ARV treatments in developing countries

>40% of all patients globally being treated for HIV/AIDS depend on a Mylan product.

Stock photos.
Posed by models.

Innovating to Meet Unmet Needs

At Mylan, we have a long tradition of innovation.


In fact, we've invested approximately $5 billion in R&D globally over the last decade. And whether we’re developing more affordable versions of insulins, biologics or respiratory therapies, better health for a better world is our goal.


Watch The Mylan Story

Investing for Now and the Future

Innovation occurs around the clock in more than a dozen R&D sites worldwide. Mylan has:


2 Global R&D Centers
including one in West Virginia
12 Tech-Focused R&D sites
including one in Texas and one in Vermont

~3,000
scientists and regulatory affairs experts globally
>4,200
active patents
>1,800
new product submissions pending approval worldwide
Mylan has long ranked among the top companies receiving FDA approvals for generic drug applications, obtaining >130 approvals in the last three years alone.
Challenging the Status Quo

Mylan takes on challenges no one else will, developing innovative, cost-effective and patient-friendly treatments for diseases like cancer, diabetes, HIV/AIDS and more.

For example, lack of refrigeration once meant lack of access to certain antiretroviral (ARV) medicines for millions of HIV/AIDS patients in developing countries. Our scientists responded by making heat-stable formulations.

And Mylan's innovations go way beyond medicines. Our services and patient-support programs address a wide range of health issues.


Watch how Mylan helps HIV/AIDS patients in the developing world

Delivering Medicine the Way Patients Need It
From tablets and capsules, injectables and ointments to inhalers and transdermals – Mylan provides patients the medicine they need, the way they need it.

Manufacturing Capacity

80B
oral solid doses, such as tablets and capsules
500M
units of injectable medicines
1.5B
complex products, such as transdermal patches, topical products and respiratory therapies
Driving Access to Advanced Treatments

Mylan is known for producing "difficult-to-develop" medicines. Many are used to treat diseases like cancer, autoimmune disorders, chronic obstructive pulmonary disease (COPD) and diabetes.



Mylan has 16 biosimilar and insulin analog products on the market or in development worldwide.

They include 8 of the top 10 biologics in areas of oncology, immunology, endocrinology and ophthalmology.


Your Voice is Our Voice

One of the most powerful ways to serve patients in need is by speaking out on their behalf.


Mylan works with government, trade associations, healthcare providers, patient-advocacy groups and others to shape policies that help people across the nation enjoy better health.

Making Medicine More Accessible

Mylan has a decades-long track record of expanding people’s access to medicine, particularly by making more-affordable generic versions of brand name drugs – expertise we’re now bringing to biologics, insulins and other complex medicines.


In the U.S., Mylan:


1982

Helped establish the generic industry’s first trade association

1984

Gave rise to legislation creating the modern generics industry

2003

Helped modernize Medicare, including the introduction of a prescription-drug be

2012

Led the way to ensure one quality standard for all medicines sold in the U.S.


A circle chart showing 19 percent
1984

Generic drugs made up only 19% of prescriptions dispensed in the U.S.

A circle chart showing 89 percent
2016

Last year, they made up 89% of prescriptions dispensed.


Generics make up 89% of prescriptions dispensed in the U.S.,

yet represent only 27% of total drug spending.

Biosimilars

The introduction of just 11 biosimilars in the U.S. could save the nation’s healthcare system $250 billion over 10 years.

Mylan has 16 biosimilar and insulin analog products on the market around the world or in development. They include eight of the world’s top 10 biologics.

Addressing an Important Need in Schools

Epinephrine is the only first-line treatment for anaphylaxis, a potentially life-threatening allergic reaction. Several years ago, we recognized that epinephrine auto-injectors needed to be as accessible as defibrillators are in public spaces. So Mylan advocated for legislation to permit “undesignated” epinephrine auto-injectors in schools – meaning a prescription could be in a school’s name rather than in a child’s name and any individual experiencing an anaphylactic emergency would have access to the epinephrine auto-injectors. Today, 48 states have adopted such laws, and Mylan has donated nearly 1 million epinephrine auto-injectors to more than 73,000 schools around the country.

Stemming the Tide of HIV/AIDS

Stock photos.
Posed by models.

Helping those in need is a gift that benefits everyone.

Mylan is the world’s largest producer of HIV/AIDS drugs.

>40%

of all people being treated for HIV/AIDS depend on a Mylan antiretroviral product.

>50%

of Mylan’s active pharmaceutical ingredient manufacturing capacity is devoted to antiretrovirals.

Doing Good

At Mylan, making the world a better place is in our DNA. Whether we are providing good jobs for our workforce, donating medicines to clinics, or supporting a little league baseball team, Mylan strengthens communities.

Workforce in the U.S.

~7,000

Science & Technology jobs in the U.S.

~2,500

Supporting the U.S. Economy

High Quality Jobs, High Quality Employer

Mylan employs thousands of people in manufacturing, science and technology jobs in the U.S. and elsewhere — and we encourage our entire workforce to challenge the status quo.

35%

of Mylan’s U.S. workforce works in a scientific or technology role.

22%

of Mylan’s global workforce took on new roles in 2016.

60%

of Mylan’s U.S. workforce is directly responsible for production of medicines.

46%

of Mylan’s global workforce are millennials.

Partnering With the Community

Mylan understands that it takes a village to sustain a village, so we look for opportunities to donate medicines we produce to those who need them most.


Since 2007

114M+

doses of medicine donated in the U.S.

2.2B

doses of medicine donated worldwide

Philanthropic Impact

Mylan Cares

Soon after Mylan was founded in rural West Virginia in 1961, "giving back" became a core value and common practice. Examples of organizations we've supported recently include the American Cancer Society, American Heart Association, American Red Cross, Habitat for Humanity, Hugh O'Brien Youth Leadership and National MS Society.

Awareness, Preparedness & Access to Treatment for Anaphylaxis

Mylan’s commitment to expanding access to medicine extends beyond just offering products. Take potentially life-threatening allergic reactions, or anaphylaxis. These reactions can occur quickly and without warning. The rate of reported severe allergic reactions to food alone has increased by nearly five times over the past decade. An estimated one in 13 children is affected by food allergies, a common trigger for anaphylaxis, and as many as one in 20 adults in the U.S. are at risk.

Mylan has worked hard to get the word out about the importance of avoiding allergic triggers, being prepared in case anaphylaxis occurs and ensuring that effective treatment is at hand when needed.

Learn more about what we have done to improve access through our resources here.

Up to 43 million people may have allergic sensitivities that put them at risk.

Every 6 minutes food-related anaphylaxis sends someone to the emergency room.

1 in 3

Epinephrine is the only first-line treatment for anaphylaxis.

Yet according to a recent study, 1 in 3 patients prescribed epinephrine failed to carry their medication during a reported anaphylactic event.

25%

Approximately 25% of life-threatening allergic reactions reported at schools, for example, have occurred in those with no previous diagnosis of a food allergy.

EpiPen4Schools®

In 2012, Mylan launched the EpiPen4Schools program. It provides four FREE epinephrine auto-injectors to qualifying* U.S. public and private kindergarten, elementary, middle and high schools, along with additional training and educational resources.


>1M

Over the past five years, more than 1,000,000 free epinephrine auto-injectors have been provided to more than 73,000 schools nationwide, approximately 54% of schools.


Since the program began in 2012, epinephrine auto-injectors provided through the EpiPen4Schools program have been used more than 2,000 times across nearly every state to treat an anaphylactic reaction in the school setting. This reinforces the need for increased access to treatment in schools.

 Learn how schools can enroll in the program at EpiPen4Schools.com

A Deeper Look

EpiPen4Schools is making a difference, according to data from a survey of program participants during the 2014-2015 school year. Anaphylaxis occurred across all grade levels and in individuals with and without known risk factors, underscoring the need for school preparedness.

Survey results highlights:

  • In anaphylactic events when an epinephrine auto-injector was used, nearly half were treated with an EpiPen® Auto-Injector provided by the EpiPen4Schools® program.
  • A substantial proportion of anaphylactic events occurred in students with no known history of severe allergies.
  • Higher anaphylactic event rates occur among high school students compared with younger grade levels.

Advancing Public Policy

As part of our ongoing commitment to increase access to treatment, Mylan partnered with advocacy groups and public policy leaders to back legislation that would permit undesignated, or “stock,” epinephrine auto-injectors, not specific to any brand or student, in schools. We knew it would not be easy and would take time, but Mylan has remained committed to supporting this important community, and significant progress has been made.


8 to 48

In 2010, only eight states had legislation that allowed undesignated, or “stock,” epinephrine in schools. Today, 48 states have enacted laws or policies allowing it.


We’re not stopping there. We’ve also been working to make undesignated epinephrine auto-injectors available in other public places, such as restaurants, colleges and universities. As a result, stock epinephrine in public places now is permitted in 31 states.

A recent survey conducted by the U.S. Centers for Disease Control found that in nearly half of peanut and tree nut allergic reactions in restaurants or other food-service establishments, the food allergic customers had alerted the restaurant to their severe allergy in advance.

Important Safety Information

Use EpiPen® (epinephrine injection, USP) 0.3 mg or EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors right away when you have an allergic emergency (anaphylaxis). Get emergency medical help right away. You may need further medical attention. Only a healthcare professional should give additional doses of epinephrine if you need more than two injections for a single anaphylactic episode. EpiPen® or EpiPen Jr® should only be injected into the middle of your outer thigh (upper leg), through clothing if necessary. Do not inject into your veins, buttocks, fingers, toes, hands or feet. Hold the leg of young children firmly in place before and during injection to prevent injuries. In case of accidental injection, please seek immediate medical treatment.

Rarely, patients who have used EpiPen® or EpiPen Jr® may develop an infection at the injection site within a few days. Some of these infections can be serious. Call your healthcare professional right away if you have any of the following at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Tell your healthcare professional about all of your medical conditions, especially if you have asthma, a history of depression, thyroid problems, Parkinson’s disease, diabetes, high blood pressure or heart problems, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your healthcare professional all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you use EpiPen® or EpiPen Jr®.

Common side effects include fast, irregular or “pounding” heartbeat, sweating, nausea or vomiting, breathing problems, paleness, dizziness, weakness, shakiness, headache, feelings of over excitement, nervousness or anxiety. These side effects usually go away quickly if you lie down and rest. Tell your healthcare professional if you have any side effect that bothers you or that does not go away.

Indications

EpiPen® and EpiPen Jr® Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. EpiPen® and EpiPen Jr® are intended for immediate administration as emergency supportive therapy only. Seek immediate emergency medical help right away.

Please see the full Prescribing Information and Patient Information.

For additional information please contact us at 800-395-3376.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.



Back to top
Learn more at Mylan.com

Important Safety Information

Use EpiPen® (epinephrine injection, USP) 0.3 mg or EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors right away when you have an allergic emergency (anaphylaxis). Get emergency medical help right away. You may need further medical attention. Only a healthcare professional should give additional doses of epinephrine if you need more than two injections for a single anaphylactic episode. EpiPen® or EpiPen Jr® should only be injected into the middle of your outer thigh (upper leg), through clothing if necessary. Do not inject into your veins, buttocks, fingers, toes, hands or feet. Hold the leg of young children firmly in place before and during injection to prevent injuries. In case of accidental injection, please seek immediate medical treatment.

Rarely, patients who have used EpiPen® or EpiPen Jr® may develop an infection at the injection site within a few days. Some of these infections can be serious. Call your healthcare professional right away if you have any of the following at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Tell your healthcare professional about all of your medical conditions, especially if you have asthma, a history of depression, thyroid problems, Parkinson’s disease, diabetes, high blood pressure or heart problems, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your healthcare professional all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you use EpiPen® or EpiPen Jr®.

Common side effects include fast, irregular or “pounding” heartbeat, sweating, nausea or vomiting, breathing problems, paleness, dizziness, weakness, shakiness, headache, feelings of over excitement, nervousness or anxiety. These side effects usually go away quickly if you lie down and rest. Tell your healthcare professional if you have any side effect that bothers you or that does not go away.

Indications

EpiPen® and EpiPen Jr® Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. EpiPen® and EpiPen Jr® are intended for immediate administration as emergency supportive therapy only. Seek immediate emergency medical help right away.